Applications, Limitations, and Considerations of Clinical Trials in a Dish

Overview

Journal Bioengineering (Basel)

Date 2024 Nov 27

PMID 39593756

Authors

Amatullah Mir

Angie Zhu

Rico Lau

Nicolas Barr

Zyva Sheikh

Diana Acuna

Anuhya Dayal

Narutoshi Hibino

Affiliations

Soon will be listed here.

Abstract

Recent advancements in biotechnology forged the path for clinical trials in dish (CTiDs) to advance as a popular method of experimentation in biomedicine. CTiDs play a fundamental role in translational research through technologies such as induced pluripotent stem cells, whole genome sequencing, and organs-on-a-chip. In this review, we explore advancements that enable these CTiD biotechnologies and their applications in animal testing, disease modeling, and space radiation technologies. Furthermore, this review dissects the advantages and disadvantages of CTiDs, as well as their regulatory considerations. Lastly, we evaluate the challenges that CTiDs pose and the role of CTiDs in future experimentation.

References

Martin R, Biswas P, Freemantle S, Pearce G, Mann R . Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998; 46(5):505-11. PMC: 1873702. DOI: 10.1046/j.1365-2125.1998.00817.x. View

Granata A, Serrano F, Bernard W, McNamara M, Low L, Sastry P . An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat Genet. 2016; 49(1):97-109. DOI: 10.1038/ng.3723. View

Holmgren G, Synnergren J, Bogestal Y, Ameen C, Akesson K, Holmgren S . Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 2014; 328:102-11. PMC: 4326176. DOI: 10.1016/j.tox.2014.12.018. View

Ahmed S, Shivnaraine R, Wu J . FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish. Circulation. 2023; 148(4):309-311. PMC: 10902210. DOI: 10.1161/CIRCULATIONAHA.123.065585. View

Fermini B, Coyne S, Coyne K . Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development. SLAS Discov. 2018; 23(8):765-776. PMC: 6104197. DOI: 10.1177/2472555218775028. View

Louisse J, Wust R, Pistollato F, Palosaari T, Barilari M, Macko P . Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol In Vitro. 2017; 42:182-190. DOI: 10.1016/j.tiv.2017.04.023. View

Shinozawa T, Nakamura K, Shoji M, Morita M, Kimura M, Furukawa H . Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports. 2017; 8(2):226-234. PMC: 5312248. DOI: 10.1016/j.stemcr.2016.12.014. View

Johannesen L, Vicente J, Mason J, Erato C, Sanabria C, Waite-Labott K . Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. Clin Pharmacol Ther. 2015; 99(2):214-23. PMC: 5421403. DOI: 10.1002/cpt.205. View

Grskovic M, Javaherian A, Strulovici B, Daley G . Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011; 10(12):915-29. DOI: 10.1038/nrd3577. View

10.

Lutolf M, Blau H . Artificial stem cell niches. Adv Mater. 2010; 21(32-33):3255-68. PMC: 3099745. DOI: 10.1002/adma.200802582. View

11.

Webb S . The gold rush for induced pluripotent stem cells. Nat Biotechnol. 2009; 27(11):977-9. DOI: 10.1038/nbt1109-977. View

12.

Bogin V . Lasagna's law: A dish best served early. Contemp Clin Trials Commun. 2022; 26:100900. PMC: 8847811. DOI: 10.1016/j.conctc.2022.100900. View

13.

Wainger B, Buttermore E, Oliveira J, Mellin C, Lee S, Saber W . Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts. Nat Neurosci. 2014; 18(1):17-24. PMC: 4429606. DOI: 10.1038/nn.3886. View

14.

Roberts S, Fischhoff M, Sakowski S, Feldman E . Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death". Acad Med. 2012; 87(3):266-70. DOI: 10.1097/ACM.0b013e3182446fa3. View

15.

Lin Y, Zou J . Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells in Fully Chemically Defined Conditions. STAR Protoc. 2020; 1(1). PMC: 7392178. DOI: 10.1016/j.xpro.2020.100015. View

16.

Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y . Organoids: The current status and biomedical applications. MedComm (2020). 2023; 4(3):e274. PMC: 10192887. DOI: 10.1002/mco2.274. View

17.

James E, Tomaskovic-Crook E, Crook J . Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells. Int J Mol Sci. 2021; 22(6). PMC: 8001925. DOI: 10.3390/ijms22063005. View

18.

Reimche L, Forster A, van Walraven C . Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol. 2010; 51(7):1043-50. DOI: 10.1177/0091270010378858. View

19.

DiMasi J, Grabowski H, Hansen R . Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20-33. DOI: 10.1016/j.jhealeco.2016.01.012. View

20.

Capulli A, Tian K, Mehandru N, Bukhta A, Choudhury S, Suchyta M . Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip. 2014; 14(17):3181-6. PMC: 4117800. DOI: 10.1039/c4lc00276h. View